PhenomeX (Nasdaq:CELL) - Aktienkurs, Nachrichten und Analyse

CELL Aktienübersicht

PhenomeX Inc. operates as a functional cell biology company. Mehr Details

CELL grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	3/6
Künftiges Wachstum	2/6
Vergangene Leistung	0/6
Finanzielle Gesundheit	4/6
Dividenden	0/6

Belohnungen

Prognostiziertes jährliches Umsatzwachstum 23.43%

Im Vergleich zu Wettbewerbern und der Branche gut bewertet

Risikoanalyse

Stark schwankender Aktienkurs in den letzten 3 Monaten

Hat weniger als 1 Jahr Cash Runway

Hat keine nennenswerte Marktkapitalisierung ($100M)

Die Aktionäre wurden im vergangenen Jahr verwässert

+ 1 mehr Risiko

PhenomeX Inc. Wettbewerber

Akoya Biosciences

NasdaqGS:AKYA

US$104.6m

Harvard Bioscience

NasdaqGM:HBIO

US$99.0m

Champions Oncology

NasdaqCM:CSBR

US$61.9m

Seer

NasdaqGS:SEER

US$143.3m

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für PhenomeX
Historische Aktienkurse
Aktueller Aktienkurs	US$1.00
52-Wochen-Hoch	US$3.65
52-Wochen-Tief	US$0.38
Beta	0.94
11 Monat Veränderung	2.90%
3 Monate Veränderung	116.98%
1 Jahr Veränderung	-68.21%
33 Jahre Veränderung	-98.85%
5 Jahre Veränderung	n/a
Veränderung seit IPO	-98.48%

Aktuelle Nachrichten und Updates

Recent updates

Analyst Forecasts Just Became More Bearish On PhenomeX Inc. (NASDAQ:CELL)

May 16

PhenomeX Inc.'s (NASDAQ:CELL) Subdued P/S Might Signal An Opportunity

Apr 17

Analysts Just Made A Major Revision To Their Berkeley Lights, Inc. (NASDAQ:BLI) Revenue Forecasts

Aug 15

Berkeley Lights: Optofluidic Technology Presents Strong Upside, May Redefine Therapeutic Development

Jun 09

Berkeley Lights Q1 2021 Earnings Preview

May 10

Aktionärsrenditen

	CELL	US Life Sciences	US Markt
7D	0.5%	2.8%	2.2%
1Y	-68.2%	2.9%	31.6%

Rendite im Vergleich zur Industrie: CELL unter dem Niveau der Branche US Life Sciences , die im vergangenen Jahr eine Rendite von 2.9% erzielte.

Rendite vs. Markt: CELL hinter dem Markt US zurück, der im vergangenen Jahr eine Rendite von 31.6 erzielte.

Preisvolatilität

Is CELL's price volatile compared to industry and market?
CELL volatility
CELL Average Weekly Movement	40.4%
Life Sciences Industry Average Movement	8.5%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.7%
10% least volatile stocks in US Market	3.1%

Stabiler Aktienkurs: CELLDer Aktienkurs des Unternehmens war in den letzten 3 Monaten unbeständig.

Volatilität im Zeitverlauf: CELLDie wöchentliche Volatilität der Aktie ist im vergangenen Jahr von 23% auf 40% gestiegen.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
n/a	285	Siddhartha Kadia	phenomex.com

PhenomeX Inc.'s Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von PhenomeX im Vergleich zum Marktanteil des Unternehmens?
CELL grundlegende Statistiken
Marktanteil	US$99.63m
Gewinn(TTM)	-US$124.53m
Umsatz(TTM)	US$71.82m

1.4x

Kurs-Umsatz-Verhältnis

-0.8x

Kurs-Gewinn-Verhältnis

Ist CELL zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
CELL Gewinn- und Verlustrechnung (TTM)
Einnahmen	US$71.82m
Kosten der Einnahmen	US$25.32m
Bruttogewinn	US$46.50m
Sonstige Ausgaben	US$171.03m
Umsatz	-US$124.53m

Zuletzt gemeldete Gewinne

Jun 30, 2023

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	-1.25
Bruttomarge	64.75%
Nettogewinnspanne	-173.40%
Schulden/Eigenkapital-Verhältnis	0%

Wie hat sich CELL auf lange Sicht entwickelt?

Historische Performance und Vergleiche

CELL Aktienübersicht

Belohnungen

Risikoanalyse

PhenomeX Inc. Wettbewerber

NasdaqGS:AKYA

US$104.6m

NasdaqGM:HBIO

US$99.0m

NasdaqCM:CSBR

US$61.9m

NasdaqGS:SEER

US$143.3m

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Bruker Cellular Analysis, Inc. Files Form 15

Phenomex Announces Opto Memory B Discovery Human Workflow on the Beacon®? Optofluidic Platform

PhenomeX Inc. Announces the Release of SpotLight™ Human Lambda Reagent for the Beacon® Platform to Accelerate Cell Line Development Workflows

Phenomex Unveils Meteor Chips for Quantitative Bulk Analysis on the Isospark™ Platform to Revolutionize High Throughput Multiplexed Hands-Free Proteomics

Consensus EPS estimates upgraded to US$1.13 loss

Consensus EPS estimates fall by 22%

Recent updates

Bruker Cellular Analysis, Inc. Files Form 15

Phenomex Announces Opto Memory B Discovery Human Workflow on the Beacon®? Optofluidic Platform

PhenomeX Inc. Announces the Release of SpotLight™ Human Lambda Reagent for the Beacon® Platform to Accelerate Cell Line Development Workflows

Phenomex Unveils Meteor Chips for Quantitative Bulk Analysis on the Isospark™ Platform to Revolutionize High Throughput Multiplexed Hands-Free Proteomics

Consensus EPS estimates upgraded to US$1.13 loss

Consensus EPS estimates fall by 22%

Price target decreased by 29% to US$4.00

Bruker Corporation (NasdaqGS:BRKR) signed a definitive agreement to acquire all of the outstanding shares of PhenomeX Inc. (NasdaqGS:CELL).

New major risk - Share price stability

New major risk - Financial position

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

PhenomeX Inc. to Report Q2, 2023 Results on Aug 14, 2023

PhenomeX Inc. Announces Lifting of the Stay in AbCellera Patent Infringement Case

PhenomeX Inc.(NasdaqGS:CELL) dropped from Russell Small Cap Comp Value Index

PhenomeX Receives a Notice from Nasdaq Regarding Minimum Bid Price Rule

PhenomeX Inc. Launches Beacon Quest™? Optofluidic System with Opto®? T Cell Profiling Workflows

Price target decreased by 31% to US$5.67

Consensus revenue estimates decrease by 16%, EPS upgraded

PhenomeX Inc. Launches Beacon Select Optofluidic System with Opto B Discovery Workflows

Analyst Forecasts Just Became More Bearish On PhenomeX Inc. (NASDAQ:CELL)

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

PhenomeX Inc. Provides Earning Guidance for the Full Year of 2023

PhenomeX Inc.'s (NASDAQ:CELL) Subdued P/S Might Signal An Opportunity

Full year 2022 earnings: EPS and revenues miss analyst expectations

Berkeley Lights, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Berkeley Lights, Inc. Provides Preliminary Revenue Guidance for the Year Ended December 31, 2022

Berkeley Lights, Inc. (NasdaqGS:BLI) announced a definitive agreement to acquire IsoPlexis Corporation (NasdaqGS:ISO) from a group of shareholders for $56.3 million.

CEO & Director notifies of intention to sell stock

President of Global Operations notifies of intention to sell stock

Berkeley Lights Accelerating Antibody Discovery with Launch of Rabbit Memory B Cell Workflow

High number of new directors

Third quarter 2022 earnings: EPS misses analyst expectations

Berkeley Lights, Inc. Provides Revenue Guidance for the Year 2022

Berkeley Lights, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Berkeley Lights, Inc. Announces Appointment of Scott Chaplin as Chief Legal Officer and Corporate Secretary

CEO & Director notifies of intention to sell stock

President of Global Operations notifies of intention to sell stock

Consensus revenue estimates fall by 17%

Analysts Just Made A Major Revision To Their Berkeley Lights, Inc. (NASDAQ:BLI) Revenue Forecasts

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Berkeley Lights, Inc. Provides Revenue Guidance for the Full Year 2022

Berkeley Lights, Inc. and the Jaime Leandro Foundation Announce the Discovery, Functional Characterization, and Recovery of A Patient-Derived T Cell Receptor Sequence Against A Cancer Neoantigen

Berkeley Lights, Inc. Announces Appointment of Dr. Rolando Brawer as Executive Vice President, Strategy & Corporate Development

Berkeley Lights Inc. Announces Mehul Joshi as New Chief Financial Officer

Mehul Joshi joins Berkeley Lights as CFO

Berkeley Lights, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Insider notifies of intention to sell stock

First quarter 2022 earnings: EPS misses analyst expectations

Price target decreased to US$16.80

High number of new directors

Berkeley Lights, Inc., Annual General Meeting, May 26, 2022

Berkeley Lights Announces Appointment of Lucas S. Vitale as Chief Human Resources Officer

Insider recently bought US$502k worth of stock

Berkeley Lights, Inc. Releases Upgrade to Its Software Suite for Beacon and Lightning Platforms

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Berkeley Lights, Inc. Reiterates Revenue Guidance for Full Year 2022

Price target decreased to US$30.40

Berkeley Lights, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Robbins Geller Rudman & Dowd LLP Files Class Action Suit Against Berkeley Lights, Inc. and Announces Opportunity for Investors with Substantial Losses to Lead Case

Erträge & Einnahmen